Trial Profile
Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 17 Dec 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
- 28 Jul 2008 Status changed from in progress to completed
- 28 Jul 2008 Results have been published